Accordingly, in a wide range of human cancers, CD47 expression levels are associated with a worse outcome, and multiple clinical trials have started to evaluate its neutralization by monoclonal antibodies, in particular by combinatory strategies [199,200]. This evidence concerns the gene CD47 and cancer.